← Russell 3000 cross-section

ARCT Arcturus Therapeutics Holdings Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$449m
Revenue TTM
$29m
Net income TTM
$-93m
Free cash flow
$-73m
Composite score
33.1
Sector rank
#2444

Valuation

P / E
EV / EBITDA
EV / sales
8.8
FCF yield
-16.23%
Earnings yield vs 10-yr
-25.52pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-317.6%
EBITDA margin
ROE
-54.3%
ROIC
Revenue growth
-76.0%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Total deferred revenue as of June 30, 2026 and December 31, 2025 for the CSL Collaboration Agreement was $ 5.2 million and $ 6.2 million, respectively. The costs associated with these reimbursements are reflected as a component of research and development expense in the Company’s condensed consolidated statements of operations and comprehensive loss. As of June 30, 2026, the remaining available funding net of revenue e arned was $ 24.6 million. Sales Agreement On December 23, 2022, the Company entered into a Controlled Equity Offering℠ Sales Agreement, which was amended on August 7, 2023 (as amended, the “Sales Agreement”) with Cantor Fitzgerald & Co. …Arcturus Therapeutics Holdings Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →